Skip to content

Clinical study of Chaiqin Xiaogan decoction in the treatment of granulomatous lobular mastitis (type of liver meridian accumulation heat)

Clinical study of Chaiqin Xiaogan decoction in the treatment of granulomatous lobular mastitis (type of liver meridian accumulation heat)

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076875
Enrollment
Unknown
Registered
2023-10-23
Start date
2023-10-30
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Granulomatous lobular mastitis

Interventions

treatment group:Chaiqinxiaongyongyin granules

Sponsors

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1.It meets the diagnostic criteria of GLM and is of the liver meridian heat type; 2.Patients with disease duration within 1 month and not receiving antibiotics, hormones, anti-tuberculosis drugs, immunotherapy, surgical treatment (including incision and drainage of an abscess), and who are required to undergo medication for conservative treatment of the masses; 3.Females aged between 18 and 45 years old; 4.After learning about the study, they will be informed and agree to participate in the trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with breast malignancies, other endocrine diseases, psychiatric disorders, autoimmune diseases, inflammatory diseases that may exhibit similar or identical symptoms to this disease; 2.Combined with other breast diseases, the drugs taken may affect the results of this experiment; 3.Patients with combination of serious cardiovascular and cerebrovascular diseases, liver and kidney insufficiency and other primary diseases; 4.Pregnant and lactating women; 5.allergy or known hypersensitivity to such drugs or constituents.

Design outcomes

Primary

MeasureTime frame
Disease response rate;

Secondary

MeasureTime frame
routine blood test;Blood sedimentation;Ultrasound elastic stiffness value at the largest lesion;VAS score for breast pain;

Countries

china

Contacts

Public ContactMeng Tian

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

mtnaicha@126.com+86 137 6410 9305

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026